About the Foundation

CHRONOS19 WILL BE PRESENTED AT THE EHA 2021 VIRTUAL CONGRESS

The results of the subgroup analysis of the CHRONOS19 registry in patients with acute leukemia and COVID-19 will be presented orally by the study PI Olga ... далее...

Loss of heterozygosity in the short tandem repeat (STR) loci found in tumor DNA of ALL patients as a factor predicting poor outcome National Research Center for ... далее...

CHRONOS19: INTERIM ANALYSIS OF THE OBSERVATIONAL STUDY OF COVID-19 IN PATIENTS WITH BLOOD DISEASES

The emergence of a new infectious disease COVID-19 led to the extensive research of not only the coronavirus itself, but also the course of this disease in ... далее...

Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome: Interim Results Of The Study

This study was supported by RakFond, Grant No. 5/2019 KEY WORDS: Loss of heterozygosity (LOH), de novo diagnosed ALL, chromosome aberration, hidden chromosomal ... далее...

CHRONOS19 WILL BE PRESENTED AT THE EHA 2021 VIRTUAL CONGRESS

The results of the subgroup analysis of the CHRONOS19 registry in patients with acute leukemia and COVID-19 will be presented orally by the study PI Olga ... далее...

Bright scientific events in oncology in 2020

Author: Alexey Tikhonov 2020 was marked by a large number of striking events in the oncology field, and in this material, I would like to highlight a number of ... далее...

Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome: Interim Results Of The Study

This study was supported by RakFond, Grant No. 5/2019 KEY WORDS: Loss of heterozygosity (LOH), de novo diagnosed ALL, chromosome aberration, hidden chromosomal ... далее...

PLATINUM-BASED CHEMOTHERAPY IN TREATMENT OF PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

Ovarian cancer is one of the most sensitive tumors to chemotherapy - in most cases it is possible to achieve complete tumor regression affected by modern drug ... далее...

Interview with Tatiana Semiglazova

Interview with Tatiana Semiglazova, MD, DSci, Professor, Head of Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology (St. Petersburg, Russia), Professor at the Department of Oncology, I.I. Mechnikov North-Western State Medical University (St. Petersburg, Russia)...The topic of the interview is the rehabilitation of cancer patients... далее...

Interview with Andrei Gudkov

Interview with Andrei Gudkov, Ph.D., D.Sci., Senior Vice President, Research Technology and Innovation, Chair, Cell Stress Biology, Roswell Park Comprehensive Cancer Center (Buffalo, USA), Member of RakFond's Scientific Advisory Board... Learn about the relationship between cancer and evolution, what the scientists may be proud of, and where the curiosity leads us... далее...

Interview with Jacek Gronwald

Interview with Jacek Gronwald, PhD, Professor, Department of Genetics and Pathology, Pomeranian Medical University (Szczecin, Poland), Member of RakFond's Scientific Advisory Board. Learn about hereditary cancers, studies of lifestyle factors in oncology... далее...

Interview with Alexey Danilov

Interview with Alexey Danilov, Associate Professor of Medicine, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University (Portland, USA), Member of RakFond's Scientific Advisory Board...Learn about research translation from bench to bedside, the discovery and research of the novel therapies in hematologic malignancies... далее...